Slakter Jason Scott

Avg. Two Year Performance

(85%) Avg. Purchase Return
(36%) Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return24%(24%)(27%)(58%)(85%)
Purchase Success Rate3 of 81 of 82 of 81 of 80 of 8
Average Sale Return----------
Sale Success Rate----------

Ohr Pharmaceutical, Inc.

Drugs » Biotechnology

Chief Executive Officer, Director:

Holdings: 2.26M shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--